Kura Oncology, INC

Kura Oncology has established a new subsidiary, Caspian Therapeutics, to focus on cardiometabolic diseases, raising $50 million in Series A financing and contributing key assets.

Kura Oncology, Inc. announced the appointment of Jennifer Fulk as Chief Financial Officer, effective September 8, 2026, detailing her compensation and equity awards.

Kura Oncology announced robust second quarter 2026 financial results, highlighted by significant revenue growth for KOMZIFTI and promising clinical updates for its pipeline assets.

Kura Oncology has amended executive employment agreements, modifying severance provisions for key officers in the event of termination or corporate transactions.

Kura Oncology announced its fourth quarter and full year 2025 financial results, highlighting the successful early commercial launch of KOMZIFTI and significant progress in its AML and solid tumor pipelines.

Kura Oncology, Inc. has adopted amended and restated bylaws, effective January 28, 2026, introducing significant changes to corporate governance, stockholder meeting procedures, and director indemnification.

Kura Oncology announces Q2 2026 results, showing $9.1M in KOMZIFTI net product revenue, but also a net loss of $68.3M.

Kura Oncology announces first quarter 2026 results, with $5.8 million in KOMZIFTI net product revenue and continued investment in pipeline development.

Kura Oncology reports significant clinical progress for its lead cancer therapies, ziftomenib, darlifarnib, and tipifarnib, alongside increased collaboration revenue, despite widening net losses in Q3 2025.

Kura Oncology reports Q2 2025 financial results, highlighting significant progress in its ziftomenib program with FDA Priority Review and positive clinical data, alongside continued operating losses.

Kura Oncology's Q1 2025 results highlight a net loss but significant collaboration revenue from the Kyowa Kirin agreement and progress in clinical trials.

Kura Oncology's Q3 2024 report highlights ongoing clinical trials and financial stability with $455.3 million in cash, cash equivalents, and short-term investments.

Kura Oncology achieved a pivotal milestone with FDA approval and commercial launch of KOMZIFTI for relapsed or refractory NPM1-mutated AML, while advancing a diversified oncology pipeline.

Kura Oncology partners with Kyowa Kirin in a global collaboration for ziftomenib, while also reporting positive topline results from its Phase 2 KOMET-001 trial.

Kura Oncology's 2023 10-K filing details the company's financial status, clinical trial progress, and strategic direction, highlighting advancements in its precision medicine pipeline.

Teresa Brophy Bair, Chief Legal Officer of Kura Oncology, Inc., sold 8,442 shares of common stock on September 28, 2026 for $10.50 per share.

Kathleen Ford, Chief Operating Officer of Kura Oncology, Inc., sold 10,574 shares of common stock on September 28, 2026.

Mollie Leoni, Chief Medical Officer of Kura Oncology, Inc., sold 41,250 shares of common stock on September 28, 2026.

Thomas James Doyle, SVP, Finance & Accounting of Kura Oncology, Inc., sold 4,607 shares of common stock on September 28, 2026 for $10.50 per share.

Brian T. Powl, Chief Commercial Officer of Kura Oncology, Inc., sold 32,450 shares of common stock on September 28, 2026.

Troy Edward Wilson, President and CEO and a Director of Kura Oncology, Inc., purchased 100,000 shares of common stock on August 24, 2026 for $12.39 per share.

Kura Oncology, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 4, 2026, to elect directors, ratify auditor appointments, and vote on equity plan amendments.

Kura Oncology will hold its annual stockholders meeting on June 5, 2025, seeking votes on director elections, auditor ratification, executive compensation, and an equity incentive plan amendment.

Kura Oncology is holding its 2025 Annual Meeting of Stockholders to elect directors, ratify the appointment of Ernst & Young LLP, approve executive compensation, and amend the 2014 Equity Incentive Plan.

Kura Oncology will hold its annual stockholders meeting on June 5, 2024, to vote on director elections, auditor ratification, executive compensation, and an equity incentive plan amendment.

Kura Oncology is holding its 2024 Annual Meeting of Stockholders on June 5, 2024, to vote on key proposals including director elections, auditor ratification, executive compensation, and an amendment to the equity incentive plan.

Montanova Capital, Averill Master Fund, and Aaron Cowen have filed an amendment to their Schedule 13G, reporting their beneficial ownership of Kura Oncology, Inc. common stock.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 3,736,000 shares, representing 4.23% of Kura Oncology, Inc.'s common stock as of March 31, 2026.

Vanguard Capital Management has disclosed beneficial ownership of over 4.4 million shares, representing 5.01% of Kura Oncology Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership in Kura Oncology Inc. following an internal realignment.

State Street Corporation has reported a 5.7% beneficial ownership stake in Kura Oncology Inc. common stock as of December 31, 2025.

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 5.37% in Kura Oncology, Inc., holding 4,672,000 shares as of September 30, 2025.